Lymphoma News

The U.S. Food and Drug Administration Approves Brentuximab Vedotin (Adcetris) for Hodgkin Lymphoma

On November 11, 2022, the U.S. Food and Drug Administration (FDA) announced it has approved the use of brentuximab vedotin (Adcetris), for pediatric patients 2 years of age and older with previously untreated high-risk classical Hodgkin lymphoma (cHL).

diffuse large b-cell lymphoma, lymphoma

U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (BREYANZI) for Large B-Cell Lymphoma

The U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma On June 24, 2022, the U.S. Food and Drug Administration (FDA) announced it has approved the use of lisocabtagene maraleucel (liso-cel, Breyanzi), a chimeric antigen receptor…

follicular lymphoma, lymphoma

U.S. Food and Drug Administration Approves CAR T Cell Therapy for Follicular Lymphoma

FDA announced it has approved the use of tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

follicular lymphoma, lymphoma

Advocating for Answers

After 20 years of living with lymphoma, Lois Rosenblum knows firsthand the importance of a strong support system and advocating for your health. Following an initial diagnosis of follicular lymphoma in 2002 and several disease transformations since then, she’s passionate about supporting the work that the Lymphoma Research Foundation (LRF) does to power cutting-edge research to treat and defeat lymphoma.

lymphoma

Patient Perspectives: Dispelling Myths About Clinical Trials

Clinical trials are important for advancing research and can provide patients with access to the most cutting-edge treatments. LRF Associate Director of Support Services and Helpline specialist, Izumi Nakano, answers some common questions about clinical trials to help better understand the process and what to think about when considering enrolling in one.

diffuse large b-cell lymphoma, lymphoma

U.S. Food and Drug Administration Approves CAR T Cell Therapy for Large B-Cell Lymphoma

The U.S. Food and Drug Administration Approves Axicabtagene Ciloeucel (YESCARTA) for Diffuse Large B-Cell Lymphoma On April 1, 2022, the U.S. Food and Drug Administration (FDA) announced it has approved the use of axicabtagene ciloeucel (YESCARTA, Kite, a Gilead Company),…

burkitt lymphoma, diffuse large b-cell lymphoma, lymphoma

U.S. Food and Drug Administration Approves Rituximab (RITUXAN) Plus Chemotherapy for Pediatric B-cell Lymphomas

Rituximab (RITUXAN, Genentech, Inc.), a monoclonal antibody, has been approved in combination with chemotherapy for pediatric patients 6-18 months with previously untreated, advanced staged, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), and Burkitt-like lymphoma (BLL).

lymphoma

COVID-19 Vaccine Updates and FAQs

The Lymphoma Research Foundation (LRF) encourages patients, survivors, and their care partners to take information and questions back to their individual health care providers as a way of creating a dialogue and partnership about their lymphoma and treatment.

lymphoma, Mantle Cell Lymphoma

Hope Forever and a Day

For more than 23 years, Marla Briskman faced her lymphoma—enduring five relapses and six different treatments. What gave her hope? Incredible treatment advancements and the support of family, friends, and her husband and care partner, Rickey.

lymphoma

Care Partner Perspectives: Managing The Responsibilities of Caring for a Loved One

A lymphoma diagnosis not only affects the patient, but their care partners too. LRF Scientific Advisory Board member, Thomas M. Habermann, MD shares some helpful strategies on how to help cope with some of the pressures of being a care partner.

Subscribe to Our Emails. Get lymphoma and CLL resources and updates.